Question 1

What is Tango Therapeutics's P/FCF ratio?

Accepted Answer

Tango Therapeutics (TNGX) P/FCF ratio is 15.5× as of November 8, 2021. The ratio is calculated by dividing market capitalisation by trailing twelve-month free cash flow, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/FCF ratio calculated?

Accepted Answer

P/FCF = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Free Cash Flow, where Free Cash Flow = Operating Cash Flow − Capital Expenditures. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/FCF ratio?

Accepted Answer

The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.

Question 4

What is a good P/FCF ratio for Tango Therapeutics?

Accepted Answer

Mature companies that consistently convert profit into cash often trade at 15–25× P/FCF; capital-intensive businesses with lumpy capex typically trade lower. Compare against sector peers and against the company's own multi-year average — single-year P/FCF can be distorted by working-capital swings. For Tango Therapeutics specifically, the relevant sector benchmark is the current sector median of 19.7×.

Question 5

Is Tango Therapeutics's P/FCF ratio high or low?

Accepted Answer

Tango Therapeutics's P/FCF ratio of 15.5× is above its own 5-year average of 14.0× and below the sector median of 19.7×. That places the current reading at the 55th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Tango Therapeutics's historical P/FCF ratio range?

Accepted Answer

In the available daily series, Tango Therapeutics (TNGX) P/FCF ratio has ranged from a low of 11.8× in 2021 to a high of 21.3× in 2021. The 5-year average is 14.0× and the 5-year median is 14.0×.

Question 7

What was Tango Therapeutics's P/FCF ratio in 2020?

Accepted Answer

Tango Therapeutics (TNGX) P/FCF ratio at the end of 2020 was 14.5×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month free cash flow figure available at that date.

Question 8

Why does Tango Therapeutics's P/FCF ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (free cash flow). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$1.03B	−$139.93M	—	—	Dec 31, 2025
2024	$335.83M	−$132.25M	—	—	Dec 31, 2024
2023	$948.45M	−$119.51M	—	—	Dec 31, 2023
2022	$637.79M	−$116.77M	—	—	Dec 31, 2022
2021	$957.99M	−$61.36M	—	—	Dec 31, 2021
2020	$1.00B	$68.97M	14.5×	—	Dec 31, 2020


McKesson (MCK)	17.8×
Gilead Sciences (GILD)	16.9×
DexCom (DXCM)	16.9×
Pfizer (PFE)	16.7×
Humana (HUM)	16.4×
Quest Diagnostics (DGX)	16.3×
Labcorp Holdings (LH)	15.9×
Becton, Dickinson and (BDX)	14.0×
HCA Healthcare (HCA)	13.5×
Incyte (INCY)	12.9×
UnitedHealth Group (UNH)	12.5×
CVS Health (CVS)	12.4×
Universal Health Services (UHS)	12.2×
Baxter International (BAX)	12.1×
Cardinal Health (CAH)	11.3×
IQVIA (IQV)	10.7×
Bristol-Myers Squibb (BMY)	10.4×
Biogen (BIIB)	10.3×
Elevance Health (ELV)	10.0×
Zimmer Biomet Holdings (ZBH)	9.6×
Cigna (CI)	9.1×
Viatris (VTRS)	9.1×
DaVita (DVA)	6.9×
Teladoc Health (TDOC)	3.9×
Centene (CNC)	2.5×

P/FCF Ratio for Tango Therapeutics (TNGX)

P/FCF Ratio daily chart for Tango Therapeutics (TNGX)

Historical P/FCF Ratio for Tango Therapeutics (TNGX) from 2020 to 2025

About P/FCF Ratio at Tango Therapeutics (TNGX)

Tango Therapeutics P/FCF Ratio by Year

Tango Therapeutics P/FCF Ratio 2020: 14.5×

Sector peers by P/FCF Ratio — chart

Sector peers by P/FCF Ratio — table

Frequently asked questions

Tango Therapeutics (TNGX) Key Financials

P/FCF Ratio daily chart for Tango Therapeutics (TNGX)

Historical P/FCF Ratio for Tango Therapeutics (TNGX) from 2020 to 2025

About P/FCF Ratio at Tango Therapeutics (TNGX)

Tango Therapeutics P/FCF Ratio by Year

Tango Therapeutics P/FCF Ratio 2020: 14.5×

Sector peers by P/FCF Ratio — chart

Sector peers by P/FCF Ratio — table

Frequently asked questions

+What is Tango Therapeutics's P/FCF ratio?

+How is the P/FCF ratio calculated?

+What is the P/FCF ratio?

+What is a good P/FCF ratio for Tango Therapeutics?

+Is Tango Therapeutics's P/FCF ratio high or low?

+What is Tango Therapeutics's historical P/FCF ratio range?

+What was Tango Therapeutics's P/FCF ratio in 2020?

+Why does Tango Therapeutics's P/FCF ratio change over time?

Tango Therapeutics (TNGX) Key Financials